MedTrace Logo

Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS

NCT02546817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2017-10-31

No results posted yet for this study

Summary

To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism (VTE) patients and patient characteristics that are associated with bleeding among patients taking Eliquis. To identify factors that might be associated with the safety and effectiveness profile in Korean VTE patients.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-09-29
Completion
2017-09-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02546817 on ClinicalTrials.gov